CRIS Share Price

Open 2.88 Change Price %
High 2.92 1 Day 0.00 0.00
Low 2.82 1 Week 0.05 1.77
Close 2.88 1 Month 0.57 24.68
Volume 295648 1 Year 1.37 90.73
52 Week High 3.72
52 Week Low 1.47
CRIS Important Levels
Resistance 2 2.97
Resistance 1 2.93
Pivot 2.87
Support 1 2.83
Support 2 2.79
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
FTR 1.98 -1.98%
FTR 1.98 -1.98%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
SSH 2.31 32.76%
SSH 2.31 32.76%
SSH 2.31 32.76%
LTRE 2.40 31.87%
HPJ 4.90 30.67%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
ORIG 0.23 -68.49%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Curis, Inc. (NASDAQ: CRIS)

CRIS Technical Analysis 3
As on 28th Mar 2017 CRIS Share Price closed @ 2.88 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.37 & Buy for SHORT-TERM with Stoploss of 2.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRIS Target for March
1st Target up-side 2.67
2nd Target up-side 2.92
3rd Target up-side 3.17
1st Target down-side 1.95
2nd Target down-side 1.7
3rd Target down-side 1.45
CRIS Other Details
Segment EQ
Market Capital 288233760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.curis.com
CRIS Address
CRIS
4 Maguire Road
Lexington, MA 02421
United States
Phone: 617-503-6500
Fax: 617-503-6501
CRIS Latest News
Interactive Technical Analysis Chart Curis, Inc. ( CRIS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Curis, Inc.
CRIS Business Profile
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).